Wellsheet Appoints Healthcare Veteran Ryan Sadlo to Help Health Systems Modernize EHR Systems to Address Physician Burnout
New Vice President of Growth to Accelerate Commercial Operations in the Public and Private Sector
News
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.
– Efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules.
– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing; Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”
– Investigational New Drug (IND) Filing planned for late 2Q/early 3Q 2021.
Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality
Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants
Immunome Appoints Corleen Roche as Chief Financial Officer
– Seasoned biopharmaceutical executive with more than 30 years of corporate finance and business strategy experience –
Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Immunome Appoints Dr. Dennis Giesing as Chief Development Officer
– Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies –
Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
– IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing –
– IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies –
– Raised $44.9 million in gross proceeds in NASDAQ IPO –
– Program updates expected in 2Q 2021 –
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
– Renovacor, Inc. has entered into a denitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) –
– Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” –
– The business combination is expected to be completed in the second quarter of 2021 –